PGP and ovarian cancer: The recognition of Olaparib by P-gp was already reported in in vitro models such as in the overexpressing drug-resistant IGROVCDDP cisplatin-resistant ovarian cancer cell line, in the KB-8-5-11 multidrug resistant epidermal carcinoma cell line and in BRCA1-mutated mouse mammary tumors27, 28.